Pfizer Plans Gene Therapy Manufacturing Investment in North CarolinaPharmaceutical Technology MagazinePfizer is moving forward with plans to invest in a new clinical and commercial gene therapy manufacturing facility in Sanford, NC, but the work is sti… Continue reading
Pfizer Plans Gene Therapy Manufacturing Investment in North …BioPharm InternationalPfizer is moving forward with plans to invest in a new clinical and commercial gene therapy manufacturing facility in Sanford, NC, but the work is still in the … Continue reading
Medical News Today |
Aging is exacerbated by alterations of stem cell circadian rhythm …
Science Daily Two new studies refute the scientific dogma associating aging with the loss of stem cell circadian rhythm. The studies show that during aging, stem cells continue … Low-calorie diet may slow aging by ‘rejuvenating biological clock’Medical News Today |
Heavy.com |
Bo Cooper, ‘First In Human’: 5 Fast Facts You Need to Know
Heavy.com One year later, he learned that the cancer had returned, and that his only option was an experimental Car T-Cell treatment. According to MSN.com, the treatment was only available in the US and “would potentially cost hundreds of thousands of dollars.”. |
Heavy.com |
Bo Cooper, ‘First In Human’: 5 Fast Facts You Need to Know
Heavy.com One year later, he learned that the cancer had returned, and that his only option was an experimental Car T-Cell treatment. According to MSN.com, the treatment was only available in the US and “would potentially cost hundreds of thousands of dollars.”. |
|
Novel Stem Cell-Derived Model Created of Inflammatory Neurological Disorder
UC San Diego Health An international team of scientists, led by University of California San Diego School of Medicine researchers, has created a human stem cell-based model of a rare, but devastating, inherited neurological autoimmune condition called Aicardi-Goutieres … |
|
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update
GlobeNewswire (press release) “CRISPR Therapeutics has had a very productive first half of the year across all aspects of our business and we remain on track to achieve the goals we set at the beginning of the year,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “Our lead … |